Results 71 to 80 of about 48,011 (239)

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Analysis and prospect of platelet compatible transfusion

, 2022
Platelet compatible transfusion can effectively solve the immune mediated platelet transfusion refractoriness (PTR), save platelet resources and improve blood safety.
Zhixin ZHANG, Faming ZHU, Wei MAO
core   +1 more source

Nonthermal plasma approaches for combating implant‐associated infections: A compendious review

VIEW, EarlyView.
Implant‐associated infections pose serious clinical challenges. Non‐thermal plasma (NTP) modifications overcome this bottleneck in distinct ways relative to traditional sterilization methods. Gas‐phase plasmas generate highly energetic species, UV radiation and reactive oxygen/nitrogen species (RONS), which alter the implant surface properties.
A. M. Trimukhe, Satish Rojekar, Amol Gholap, K. Navaneetha Pandiyaraj, Mukesh Patekar, Claudia Riccardi, R. R. Deshmukh, Tomáš Kovářík, Kalim Deshmukh   +8 more
wiley   +1 more source

Research progress on the pathogenesis, prevention and treatment of immune platelet transfusion refractoriness

Zhongguo shuxue zazhi
Platelet transfusion refractoriness (PTR) is one of the common problems in platelet transfusion, significantly impacting patient clinical outcomes and increasing the demand for allogeneic platelet transfusion.
LI Penghui, WU Chenggao, LE Aiping
doaj   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation

Haematologica, 2018
HLA antibodies are associated with refractoriness to platelet transfusion, leading to rapid platelet clearance, sometimes coinciding with clinical side effects such as fever and chills.
Maaike Rijkers, Anno Saris, Sebastiaan Heidt, Arend Mulder, Leendert Porcelijn, Frans H.J. Claas, Ruben Bierings, Frank W.G. Leebeek, A.J. Gerard Jansen, Gestur Vidarsson, Jan Voorberg, Masja de Haas   +11 more
doaj   +1 more source

Probable sepsis‐associated encephalopathy as a component of multiple organ dysfunction syndrome in a cat with pyothorax

Australian Veterinary Journal, EarlyView.
A 2‐year‐old male neutered domestic shorthair cat with bacterial pyothorax was referred to a tertiary hospital for treatment of sepsis. He met criteria for multiple organ dysfunction syndrome and developed new‐onset neurological dysfunction subsequent to the development of sepsis.
CC Chan, CR Sharp, CJ Boyd
wiley   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon, Roseline d’Oiron, Rainer B. Zotz, Niels Bindslev, Matteo Nicola Dario Di Minno, Giovanni Di Minno   +5 more
doaj   +1 more source

Refractoriness to platelet transfusion after single-donor consecutive platelet transfusions and its relationship to platelet antibodies [PDF]

Journal of Korean Medical Science, 1988
In thirty patients with acute leukemia and severe aplastic anemia receiving random single donor platelet transfusions, the development of refractoriness by consecutive platelet transfusions with cytapheresis and its relationship to the appearance of anti-platelet antibodies were investigated.
M, Lee, B K, Kim, S, Park, C, Suh, M H, Park, M J, Cho   +5 more
openaire   +2 more sources

A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome

Immunohematology, 2019
Antibodies (Abs) against antigens on platelets (PLTs), including glycoprotein IV (CD36), can cause PLT refractoriness. Transfusing PLTs to patients with anti-CD36 is challenging because of the rarity of CD36-negative (CD36–) donors and the possibility of
S. Khatri, B. Curtis, C. Yamada
semanticscholar   +1 more source